

=> RAC and MELK

L1	0	FILE	AGRICOLA
L2	0	FILE	BIOTECHNO
L3	0	FILE	CONFSCI
L4	0	FILE	HEALSAFE
L5	0	FILE	LIFESCI
L6	0	FILE	PASCAL

TOTAL FOR ALL FILES

L7	0	RAC AND MELK
----	---	--------------

=> (maternal embryonic leucine zipper kinase)

L8	3	FILE	AGRICOLA
L9	1	FILE	BIOTECHNO
L10	2	FILE	CONFSCI
L11	0	FILE	HEALSAFE
L12	7	FILE	LIFESCI
L13	2	FILE	PASCAL

TOTAL FOR ALL FILES

L14	15	(MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE)
-----	----	--

=> l14 and RAC

L15	0	FILE	AGRICOLA
L16	0	FILE	BIOTECHNO
L17	0	FILE	CONFSCI
L18	0	FILE	HEALSAFE
L19	0	FILE	LIFESCI
L20	0	FILE	PASCAL

TOTAL FOR ALL FILES

L21	0	L14 AND RAC
-----	---	-------------

=> l14 and (RAC pathway)

L22	0	FILE	AGRICOLA
L23	0	FILE	BIOTECHNO
L24	0	FILE	CONFSCI
L25	0	FILE	HEALSAFE
L26	0	FILE	LIFESCI
L27	0	FILE	PASCAL

TOTAL FOR ALL FILES

L28	0	L14 AND (RAC PATHWAY)
-----	---	-----------------------

=> RAC pathway

L29	3	FILE	AGRICOLA
L30	17	FILE	BIOTECHNO
L31	0	FILE	CONFSCI
L32	0	FILE	HEALSAFE
L33	36	FILE	LIFESCI
L34	15	FILE	PASCAL

TOTAL FOR ALL FILES

L35	71	RAC PATHWAY
-----	----	-------------

=> l35 and kinase

L36	1	FILE	AGRICOLA
L37	11	FILE	BIOTECHNO
L38	0	FILE	CONFSCI
L39	0	FILE	HEALSAFE
L40	22	FILE	LIFESCI

L41 9 FILE PASCAL

TOTAL FOR ALL FILES

L42 43 L35 AND KINASE

=> l42 and melk

L43 0 FILE AGRICOLA
L44 0 FILE BIOTECHNO
L45 0 FILE CONFSCI
L46 0 FILE HEALSAFE
L47 0 FILE LIFESCI
L48 0 FILE PASCAL

TOTAL FOR ALL FILES

L49 0 L42 AND MELK

=> l42 and leucine

L50 0 FILE AGRICOLA
L51 0 FILE BIOTECHNO
L52 0 FILE CONFSCI
L53 0 FILE HEALSAFE
L54 0 FILE LIFESCI
L55 0 FILE PASCAL

TOTAL FOR ALL FILES

L56 0 L42 AND LEUCINE

=> file .jacob

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

7.77

7.99

FILE 'CAPLUS' ENTERED AT 15:41:35 ON 24 FEB 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:41:35 ON 24 FEB 2010

Copyright (c) 2010 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 15:41:35 ON 24 FEB 2010

FILE 'EMBASE' ENTERED AT 15:41:35 ON 24 FEB 2010

Copyright (c) 2010 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 15:41:35 ON 24 FEB 2010

CA INDEXING COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

=> melk and rac

L57 11 FILE CAPLUS
L58 0 FILE BIOSIS
L59 0 FILE MEDLINE
L60 0 FILE EMBASE
L61 39 FILE USPATFULL

TOTAL FOR ALL FILES

L62 50 MELK AND RAC

=> dup rem

ENTER L# LIST OR (END):157

PROCESSING COMPLETED FOR L57

L63 11 DUP REM L57 (0 DUPLICATES REMOVED)

=> L63 and kinase

L64 11 S L63
L65 11 FILE CAPLUS
L66 0 S L63
L67 0 FILE BIOSIS
L68 0 S L63
L69 0 FILE MEDLINE
L70 0 S L63
L71 0 FILE EMBASE
L72 0 S L63
L73 0 FILE USPATFULL

TOTAL FOR ALL FILES

L74 11 L63 AND KINASE

=> d L74 ibib abs total

L74 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:738937 CAPLUS

DOCUMENT NUMBER: 151:70264

TITLE: Stromal gene signatures for predicting the efficacy of cancer therapy

INVENTOR(S): Farmer, Pierre; Delorenzi, Mauro; Bonnefoi, Herve; Iggo, Richard

PATENT ASSIGNEE(S): Ecole Polytechnique Federale de Lausanne, Switz.

SOURCE: PCT Int. Appl., 66pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009074968	A2	20090618	WO 2008-IB55252	20081212
WO 2009074968	A3	20090924		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2007-996961P P 20071212

AB The present invention relates to a method and a kit for predicting the efficacy of cancer therapy in a subject who has undergone or is undergoing chemotherapy treatment for cancer. The Applicants have identified stromal gene signatures that predict poor pathol. response to anthracycline-based neo-adjuvant chemotherapy in two independent datasets. These signatures were shown to be a reflection of the activation state of the tumor stroma. The Applicants identified stromal genes signature that influences the response of cancers to anthracycline-based neo-adjuvant chemotherapy. The Applicants have identified several specific combinations of stromal genes, which are part of the stromal metagene and which are biomarkers for

chemosensitivity of cancer subjects to the anthracycline-based neo-adjuvant chemotherapy. Results show a significant association between response to fluorouracil (5-FU) and the stromal's metagene scores AUC 0.77; $p = 0.032$. The stromal signature predicts response to fluorouracil in rectal cancer patients.

L74 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:599273 CAPLUS

DOCUMENT NUMBER: 150:556980

TITLE: Gene expression profile in human liver cells treated by benzo[a]anthracene and the use of the genes as biomarker for monitoring benzo[a]anthracene pollution in environment

INVENTOR(S): Ryu, Jae Cheon; Kim, Yeon Jeong; Jeon, Hui Gyeong; Song, Mi Gyeong

PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea

SOURCE: Repub. Korean Kongkae Taeho Kongbo, 50pp.

CODEN: KRXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2009048057	A	20090513	KR 2007-114257	20071109
PRIORITY APPLN. INFO.:			KR 2007-114257	20071109

AB This invention provides gene expression profile in human liver cells treated by benzo[a]anthracene. The change of expression level of the genes was evaluated by comparing the gene expression level in Hep-2 cells and that in the normal liver cells. The genes provided in this invention can be used as biomarkers for monitoring benzo[a]anthracene in environment and investigating the mechanism of toxicity induced by benzo[a]anthracene.

L74 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1547187 CAPLUS

DOCUMENT NUMBER: 150:141906

TITLE: Gene expression profile in HUVEC induced by treatment of doxorubicin and its use for screening drugs inducing cardiotoxicity

INVENTOR(S): Ryu, Jae Cheon; Kim, Yeon Jeong; Song, Mi; Lee, Ha Eun

PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea

SOURCE: Repub. Korean Kongkae Taeho Kongbo, 32pp.

CODEN: KRXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2008112764	A	20081226	KR 2007-61573	20070622
KR 901127	B1	20090608		
PRIORITY APPLN. INFO.:			KR 2007-61573	20070622

AB This invention provides gene expression profile in HUVEC induced by treatment of doxorubicin treatment. The marker genes are up-regulated or down-regulated in expression after doxorubicin treatment, and screened via a DNA microarray chip. The marker genes can be used for monitoring and judging drugs or chems. with cardiotoxicity, and analyzing the reasons causing cardiotoxicity.

L74 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:1251815 CAPLUS
 DOCUMENT NUMBER: 146:26324
 TITLE: Early diagnosis of transplant rejection by analysis of gene expression profiles
 INVENTOR(S): Halloran, Philip F.
 PATENT ASSIGNEE(S): The Governors of the University of Alberta, Can.
 SOURCE: PCT Int. Appl., 168pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006125301	A1	20061130	WO 2006-CA792	20060516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060269949	A1	20061130	US 2006-434711	20060515
US 7666596	B2	20100223		

PRIORITY APPLN. INFO.: US 2005-683737P P 20050523
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 AB This document relates to methods and materials involved in detecting tissue rejection (e.g., organ rejection). For example, this document relates to methods and materials involved in the early detection of kidney tissue rejection. Genes showing changes in levels of transcription during the rejection of kidney transplants are identified for use in the early diagnosis of transplant rejection. Two major classes of transcript are identified, one group associated directly with the rejection process and a group induced by interferon γ .
 OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:817670 CAPLUS
 DOCUMENT NUMBER: 145:246599
 TITLE: Genes showing changes in levels of expression in bladder cancer and their use in diagnosis and the development of antitumor agents
 INVENTOR(S): Nakamura, Yusuke; Katagiri, Toyomasa; Nakatsuru, Shuichi
 PATENT ASSIGNEE(S): Oncotherapy Science, Inc., Japan; The University of Tokyo
 SOURCE: PCT Int. Appl., 331pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006085684	A2	20060817	WO 2006-JP302684	20060209
WO 2006085684	A9	20061019		
WO 2006085684	A3	20070329		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1856278	A2	20071121	EP 2006-713825	20060209
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2008532477	T	20080821	JP 2007-535933	20060209
EP 2011885	A2	20090107	EP 2008-13455	20060209
EP 2011885	A3	20090624		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 101175862	A	20080507	CN 2006-80011580	20071010
US 20090175844	A1	20090709	US 2008-815850	20081120
PRIORITY APPLN. INFO.:			US 2005-652318P	P 20050210
			US 2005-703225P	P 20050727
			EP 2006-713825	A3 20060209
			WO 2006-JP302684	W 20060209

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Genes that show changes in levels of expression in bladder cancer tissue compared to normal bladder are identified for use in diagnosis and as targets for therapy. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target mols. for developing drugs against the disease, and for attenuating cell growth of bladder cancer. Anal. of normal and neoplastic bladder tissue from 33 patients using an array containing 27,648 cDNAs identified 394 genes upregulated in bladder cancer and 1,272 that were down-regulated. Three genes: C2093 (MPHOSPH1); C6055 (MGC30342), and B5680N (DEPDC1), were highly informative and predictive and tested as targets for siRNA therapy. siRNAs against all three genes inhibited the growth of bladder cancer cell lines in culture.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2010 ACS ON STN

ACCESSION NUMBER: 2005:1311496 CAPLUS

DOCUMENT NUMBER: 144:49649

TITLE: Association of gene expression profiles with asthma in

INVENTOR(S): peripheral blood cells
 Kachalsky, Sylvia G.; Horev, Guy
 PATENT ASSIGNEE(S): Linkagene Ltd., Israel
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005118403	A2	20051215	WO 2005-IL590	20050605
WO 2005118403	A3	20090423		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA EP 1758792 A2 20070307 EP 2005-753551 20050605 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU US 20070148676 A1 20070628 US 2006-633063 20061201 US 2004-576599P P 20040604 WO 2005-IL590 W 20050605				

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to methods of identifying biomarkers for disease, which comprise measuring gene expression levels in subpopulations of blood cells obtained from subjects of closed populations. Particularly, the present invention relates to methods of diagnosing, monitoring and prognosing diseases comprising determining expression levels of disease-specific genes. Thus, a library of about 41,500 cDNA clones derived from the I.M.A.G.E consortium was printed in microarrays comprising the whole transcriptome and used to screen RNA isolated from leukocytes from a Cochin Jewish population known as susceptible to high occurrences of asthma. Comparison of expression profiles from asthma and non-asthma individuals identified 783 biomarker transcripts for asthma.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L74 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2010 ACS ON STN

ACCESSION NUMBER: 2005:1020555 CAPLUS

DOCUMENT NUMBER: 143:320266

TITLE: Genes with differential expression profile between human dental pulp stem cells and mesenchymal stem cells and use for regenerating tooth germ

INVENTOR(S): Ueda, Minoru; Yamada, Yoichi

PATENT ASSIGNEE(S): Hitachi Medical Corp., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 246 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005253442	A	20050922	JP 2004-111582	20040309
PRIORITY APPLN. INFO.:			JP 2004-111582	20040309

AB The present invention relates to a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells, as well as a method for regenerating tooth germ using these genes. According to the present invention, the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cell were revealed, and a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells was identified. By utilizing the groups of the genes of the present invention together with the dental pulp stem cells and mesenchymal stem cells, hard tissue such as tooth germ, dental pulp, dentin or bone can be regenerated. The present inventors investigated the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cells, resp. At first, the present inventors confirmed the differential expression of Alkaline phosphatase (ALP) activity, Dentin matrix protein 1 (DMP 1), Dentin phosphosialoprotein (DSPP) using by real time reverse-transcriptase polymerase chain reaction (RT-PCR) in total RNA from primary cultures. The number of genes in hDPSCs(I) that were up-regulated by 2>-fold, compared to hMSCs, was 614 (Table, IV). On the other hand, the number of genes down regulated by <2-fold in hDPSCs (I) was 296 (Table III, IV).

L74 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2010 ACS ON STN

ACCESSION NUMBER: 2005:158510 CAPLUS
DOCUMENT NUMBER: 142:255807
TITLE: Maternal embryonic leucine zipper kinases (MELKs) as modifiers of the RAC pathway and uses thereof in diagnosis, therapy and drug screening
INVENTOR(S): Kadyk, Lisa; Francis, George Ross; Heuer, Timothy S.; Lickteig, Kim
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016279	A2	20050224	WO 2004-US26231	20040812
WO 2005016279	A3	20050728		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SE, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG

AU 2004264936	A1	20050224	AU 2004-264936	20040812
CA 2535808	A1	20050224	CA 2004-2535808	20040812
EP 1651956	A2	20060503	EP 2004-780986	20040812

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

JP 2007502115	T	20070208	JP 2006-523383	20040812
US 20080293044	A1	20081127	US 2006-567765	20060914

PRIORITY APPLN. INFO.: US 2003-495193P P 20030814
WO 2004-US26231 W 20040812

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention has designed a dominant loss of function screen to identify genes that interact with the RAC in *C. elegans*. Maternal embryonic leucine zipper kinase (MELK) gene was identified as a modifier of the RAC pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, maternal embryonic leucine zipper kinase (MELK) genes are attractive drug targets for the treatment of pathologies associated with a defective RAC signaling pathway, such as cancer. The invention also provides methods for utilizing these RAC modifier genes and polypeptides to identify candidate therapeutic agents that can be used in the treatment of disorders associated with defective RAC function.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:718550 CAPLUS

DOCUMENT NUMBER: 141:241509

TITLE: Differentially expressed nucleic acids that correlate with KSP expression and their use as markers for diagnosis, classification, and treatment of cancer

INVENTOR(S): Huang, Pearl S.; Jackson, Jeffrey R.

PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074301	A2	20040902	WO 2004-US4276	20040213
WO 2004074301	A3	20060504		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TZ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1620449	A2	20060201	EP 2004-711130	20040213
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006521794	T	20060928	JP 2006-503555	20040213

US 20070015154 A1 20070118 US 2006-544704 20060526
 PRIORITY APPLN. INFO.: US 2003-447842P P 20030214
 WO 2004-US4276 W 20040213

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention is based on the discovery of differentially expressed nucleic acid markers that correlate pos. or neg. with expression levels of the mitotic kinesin KSP (kinesin-like 1, also termed HsEgS). Because KSP expression is increased in certain tumor types but not others, the markers can be used as surrogates for KSP (or alternatively in combination with KSP) to classify tumors into different general classes or types. The Human U133 chip set from Affymetrix comprising approx. 44,000 gene probes was used to show that breast infiltrating carcinomas fall into 3 classes. Tumors with normal KSP levels showed significant up-regulation of signal transduction genes, but significant down-regulation of cell cycle genes, whereas most tumors with high levels of KSP exhibited down-regulation of signal transduction genes and up-regulation of cell cycle genes. A third group of tumors having high KSP levels showed up-regulation of both signal transduction genes and cell cycle genes. Thus, a variety of classification, screening, diagnostic, and treatment methods are provided based upon these differentially expressed nucleic acids. Devices and kits for performing such methods are also disclosed.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:836498 CAPLUS

DOCUMENT NUMBER: 139:336483

TITLE: Gene expression profiles for diagnostic and prognostic grading of breast cancer and for drug screening

INVENTOR(S): Erlander, Mark G.; Ma, Xiao-Jun; Sgroi, Dennis C.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 28,018.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030198972	A1	20031023	US 2002-211015	20020801
US 20040002067	A1	20040101	US 2001-28018	20011221
US 20030236632	A1	20031225	US 2002-282596	20021028
WO 2003060164	A1	20030724	WO 2002-US41216	20021220
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003060470	A2	20030724	WO 2002-US41347	20021220
WO 2003060470	A3	20031113		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002358279	A1	20030730	AU 2002-358279	20021220
AU 2002360769	A1	20030730	AU 2002-360769	20021220
US 20060263806	A1	20061123	US 2006-381353	20060502
US 20060234287	A1	20061019	US 2006-426572	20060626
US 20090092973	A1	20090409	US 2007-946835	20071128

PRIORITY APPLN. INFO.:

US 2001-28018	A2	20011221
US 2002-211015	A2	20020801
US 2002-282596	A	20021028
WO 2002-US41216	W	20021220
WO 2002-US41347	W	20021220

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB This invention relates to the identification and use of gene expression patterns (or profiles or "signatures") which are correlated with (and thus able to discriminate between) cells in various stages and/or grades of breast cancer. Broadly defined, these stages are non-malignant vs. malignant, but may also be viewed as normal vs. atypical (optionally including reactive and pre-neoplastic) vs. cancerous. Another definition of the stages is normal vs. precancerous (e.g. atypical ductal hyperplasia or atypical lobular hyperplasia) vs. cancerous (e.g., carcinoma in situ such as ductal carcinoma in situ (DCIS) and/or lobular carcinoma in situ (LCIS)) vs. invasive (e.g. carcinomas such as invasive ductal carcinoma and/or invasive lobular carcinoma). The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of mol. criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer. The gene CRIP1 is especially prominent and thus may be a potential biomarker for the detection of breast cancer including the pre-malignant stage of atypical ductal hyperplasia. The epithelium-specific transcription factor ELF5 is also noteworthy since it maps to chromosome 11p13-15, a region subject to frequent loss of heterozygosity and rearrangement in multiple carcinoma including breast cancer.

L74 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:571236 CAPLUS

DOCUMENT NUMBER: 139:112797

TITLE: Gene expression profiles for diagnostic and prognostic grading of breast cancer

INVENTOR(S): Erlander, Mark G.; Ma, Xiao-Jun; Sgroi, Dennis C.

PATENT ASSIGNEE(S): Artcurus Engineering, Inc., USA; The General Hospital Corporation

SOURCE: PCT Int. Appl., 264 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2003060470	A2	20030724	WO 2002-US41347	20021220
WO 2003060470	A3	20031113		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20040002067	A1	20040101	US 2001-28018	20011221
US 20030198972	A1	20031023	US 2002-211015	20020801
AU 2002360769	A1	20030730	AU 2002-360769	20021220

PRIORITY APPLN. INFO.:	US 2001-28018	A	20011221
	US 2002-211015	A	20020801
	WO 2002-US41347	W	20021220

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB This invention relates to the identification and use of gene expression patterns (or profiles or "signatures") which are correlated with (and thus able to discriminate between) cells in various stages and/or grades of breast cancer. Broadly defined, these stages are non-malignant vs. malignant, but may also be viewed as normal vs. atypical (optionally including reactive and pre-neoplastic) vs. cancerous. Another definition of the stages is normal vs. precancerous (e.g. atypical ductal hyperplasia or atypical lobular hyperplasia) vs. cancerous (e.g., carcinoma in situ such as ductal carcinoma in situ (DCIS) and/or lobular carcinoma in situ (LCIS)) vs. invasive (e.g. carcinomas such as invasive ductal carcinoma and/or invasive lobular carcinoma). The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of mol. criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer. The gene CRIP1 is especially prominent and thus may be a potential biomarker for the detection of breast cancer including the pre-malignant stage of atypical ductal hyperplasia. The epithelium-specific transcription factor ELF5 is also noteworthy since it maps to chromosome 11p13-15, a region subject to frequent loss of heterozygosity and rearrangement in multiple carcinoma including breast cancer.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

=>